معرفی
Kuo-Ching (KC) Mei is an Assistant Professor in the Department of Pharmaceutical Sciences at Binghamton University's School of Pharmacy and Pharmaceutical Sciences. He holds a PhD in Pharmaceutical Science from King's College London and completed postdoctoral training at UCLA School of Medicine and UNC School of Pharmacy, focusing on lipid-based biomaterials and drug delivery systems. His research integrates spatial biology with molecular pharmaceutics to study tumor immune microenvironments and design next-generation therapeutics.
Education Background:
- PhD in Pharmaceutical Science – King's College London (University of London)
- MRes (Distinction) – University College London
- BS in Pharmacy – Taipei Medical University
- Postdoctoral Training – UCLA School of Medicine and UNC School of Pharmacy
Research Interests:
Dr. Mei specializes in developing therapeutic delivery systems for cancer immunotherapy, with a focus on lipid nanoparticles and liposomes. His lab investigates how tumor microenvironments influence immune interactions, enabling the design of targeted drug/gene delivery systems. Recent work includes engineering zippersomes for cardiac repair and barcoded RNA-LNP systems for organ-specific delivery.
Key Achievements:
- Received a $1.9M award to advance gene therapy for cancer through nanomedicine innovations
- Developed silicasome platforms for chemo-immunotherapy of pancreatic cancer
- Explored graphene oxide toxicity mechanisms to improve nanomedicine safety
Grant and Collaboration:
The MEI Lab collaborates on projects spanning academia and industry, with funding supporting breakthroughs in lipid-based drug delivery systems and nano-enabled immunotherapies. Current efforts emphasize translating lab discoveries into clinical applications.
Labs and Teams:
The MEI Lab at Binghamton focuses on spatially resolved molecular pharmaceutics, combining advanced imaging techniques with nanotechnology to address unmet needs in oncology and regenerative medicine.
